Temporal activation of Ca2+-calmodulin-sensitive protein kinase type II is obligate for adipogenesis.
Differentiation of 3T3-L1 embryonic fibroblasts to adipocytes in response to induction by dexamethasone and isobutylmethylxanthine is blocked by inhibitors of Ca2+-calmodulin-sensitive protein kinase type II, but not by inhibitors of protein kinase A or protein kinase C. CaM kinase II displays a biphasic increase in autonomous activity, rising after an initial transient peak from 1 to 15 h, declining at 24 h, followed by a sustained rise from 24 to 48 h, which is 2. 5-fold greater than basal values at induction of adipogenesis. Adipogenesis was blocked effectively by CaM kinase II inhibitors, either KN-62 or KN-93, if the inhibitors are introduced at 6 h and maintained until 12 h of induction of adipogenesis. Equally effective, however, is inhibition of CaM kinase II activity at 24-48 h after induction, during the later phase of autonomous CaM kinase activity. Inhibition of cultures with KN-62 or KN-93 either for 0 to 6 h or for 12 to 24 h failed to influence adipogenesis. Two temporally-distinct phases of CaM kinase II activation, either 6 to 12 h or 24 to 48 h, if inhibited with either KN-62 or KN-93, blocked the conversion to adipocytes. Thus, a biphasic activation of CaM kinase II is obligate for the progression of the embryonic fibroblasts to adipocytes. Inhibition of either phase of CaM kinase activity blocks adipogenesis and expression of several intermediate early gene products.
Wang
H y
Hy
Department of Physiology & Biophysics, Diabetes & Metabolic Diseases Research Program, University Medical Center, SUNY/Stony Brook, Stony Brook, New York 11794, USA.
Goligorsky
M S
MS
Malbon
C C
CC
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000494:pharmacology; D016475:3T3 Cells; D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism*; D002227:Carbazoles; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D051379:Mice; D011758:Pyrroles / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D000096926:Benzenesulfonamides
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D001596:Benzylamines; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D002227:Carbazoles; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D013449:Sulfonamides; C072105:KN 93; D000096926:Benzenesulfonamides; C057416:KT 5720; C063302:KN 62